Abstract
A drug discovery is characterized by two stages. The first in terms of time is called “lead structure”, followed by a so called “drug candidate” stage. The lead structure stage involves selecting the optimum molecule of the pharmaceutical, while drug candidate stage means selecting the optimum solid form. Usually, five to ten candidates pass to the drug candidate stage and the result is the selection of the final solid API (Active Pharmaceutical Ingredience) for the ensuing formulation of the solid dosage form. The lead structure stage concerns only the discovery of the original drug, the drug candidate stage may concern also generics (a drug which is bioequivalent with original and is produced and distributed after the patent protection of the original).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hájková M, Kratochvíl B, Rádl S (2008) Atorvastatin – the world’s best selling drug. Chem Listy 102:3–14
Childs SL, Hardcastle KI (2007) Cocrystals of piroxicam with carboxylic acid. Cryst Growth Des 7:1291–1304
Bingham AL, Hughes DS, Hursthouse MB, Lancaster RW, Tavener S, Threlfall TL (2001) Over one hundred solvates of sulfathiazole. Chem Commun 7:603–604
http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/GRASListings/default.htm
http://www.pharmacy.wisc.edu/SOPDir/PersonDetails.cfm?ID=32
Bernstein J (2002) Polymorphism in molecular crystals. Oxford University Press, New York, p 298
Bauer J, Sponton S, Henry R, Quick J, Dziki W, Porter W, Morfia J (2001) Ritonavir: an extraordinary example of conformational polymorphism. Pharm Res 18:859–866
Pudipeddi M, Serajuddin ATM (2005) Trends in solubility of polymorphs. J Pharm Sci 94:929–939
Bond AD, Boese R, Desiraju GR (2007) On the polymorphism of aspirin. Angew Chem Int Ed 46:615–617
Steiner T, Kellner G (1994) Crystalline beta-cyclodextrin hydrate at various humidites - fast, continuous, and reversible dehydration studies by X-ray diffraction. J Am Chem Soc 116:5122–5128
Etter MC, Urbanczyk-Lipkowska Z, Zia-Ebrahimi M, Panunto TW (1990) Hydrogen bond directed cocrystallization and molecular recognition properties of diarylureas. J Am Chem Soc 112:8415–8426
Hušák M, Kratochvíl B, Císařová I, Cvak L, Jegorov A, Böhm S (2002) Crystal forms of semisynthetic ergot alkaloid terguride. Collect Czech Chem Commun 67:479–489
Stahl PH, Wermuth CG (eds) (2002) Handbook of pharmaceutical salts: properties, selection, and use. Wiley-VCH, Weinheim
http://en.wikipedia.org/wiki/Dextropropoxyphene
Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ (2006) Pharmaceutical co-crystals. J Pharm Sci 95:499–516
Childs SL, Stahly PG, Park A (2007) The salt-cocrystal continuum: the influence of crystal structure on ionization state. Mol Pharm 4:323–338
Schultheiss N, Newman A (2009) Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9:2950–2967
Morissete SL, Almarsson Ő, Peterson ML, Remenar J, Read M, Lemmo A, Ellis S, Cima MJ, Gardner CR (2004) High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 56:275–300
Hickey MB, Peterson ML, Scoppettuolo LA, Morisette SL, Vetter A, Guzman H, Remenar JF, Zhang Z, Tawa MD, Haley S, Zaworotko MJ, Almarsson O (2007) Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm 67:112–119
Zaworotko MJ (2008) Crystal engineering of cocrystals and their relevance to pharmaceuticals and solid-state chemistry. In: XXI congress of the international union of crystallography, Book of Abstracts C11. Osaka
Jones W (2009) Multicomponent crystals in the development of new solid forms of pharmaceuticals. In: 25. European Crystallographic Meeting (ECM 25), Abstracts p. 102. Istanbul
Hilfiker R (ed) (2006) Polymorphism in the pharmaceutical industry. Wiley-VCH Verlag, Weinheim
Křen V et al (1997) Glycosylation of silybin. J Chem Soc, Perkin Trans 17:2467–2974
Nagarajan R (1993) Structure-activity relationship of vancomycin-type glycopeptide antibiotics. J Antibiot 46:1181–1195
Hancoek BC, Zografi G (1997) Characteristics and significance of amorphous state in pharmaceutical systems. J Pharm Sci 86:1–12
Teva Pharmaceutical Industries Ltd Patent WO 01/36384 A1
Accolate (2008) http://www.astrazeneca-us.com/pi/accolate.pdf
Accupro (Accupril) (2008) http://www.pfizer.com/files/products/uspi_accupril.pdf
http://www.janssen-cilag.com/product/filtered_list.jhtml?product=none
http://www.merck.com/product/usa/pi_circulars/i/indocin/indocin_cap.pdf
http://www.faqs.org/patents/app/20080293773
Parthasaradhi et al Novel polymorphs of imatinib mesylate. Patent US2005/0234069A1
Acknowledgments
This chapter was written in the framework of the project MSM 2B08021 of the Ministry of Education of the Czech Republic.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Kratochvíl, B. (2011). Solid Forms of Pharmaceutical Molecules. In: Šesták, J., Mareš, J., Hubík, P. (eds) Glassy, Amorphous and Nano-Crystalline Materials. Hot Topics in Thermal Analysis and Calorimetry, vol 8. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2882-2_8
Download citation
DOI: https://doi.org/10.1007/978-90-481-2882-2_8
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2881-5
Online ISBN: 978-90-481-2882-2
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)